Nanrilkefusp alfa
- Generic Name
- Nanrilkefusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05619172
- Locations
- 🇧🇪
Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 166
- Registration Number
- NCT05256381
- Locations
- 🇬🇪
Evex Hospitals - Caraps Medline, Tbilisi, Georgia
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 200
- Registration Number
- NCT04234113
- Locations
- 🇫🇷
Institut Gustave Roussy, Paris, France
🇪🇸University Hospital Sanchinarro, Madrid, Spain
🇫🇷Hôpitaux Universitaires de Marseille Timone, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath